| abstract |
Methods and compositions for determin-ing whether a subject is at risk for PML, including sub-jects being treated with immunosuppressants by determin-ing whether the subject harbors a ICV variant with re-duced binding for sialic acid relative to a normal ICV, are presented. Furthermore, combinations of JCV-VP1 se-quence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided |